Immunoprecipitation News and Research

RSS

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

Experts from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, presented their latest research findings about hematologic cancers at the 53rd ASH Annual Meeting and Exposition held December 10-13, 2011 in San Diego, California.

14 Dec 2011

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

The John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, will present research updates and clinical trial results of 31 cutting-edge studies at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego from December 10-13.

2 Dec 2011

Study presents high-resolution genome-wide p53-binding map for normal human cells

Scientists investigating the interactions, or binding patterns, of a major tumor-suppressor protein known as p53 with the entire genome in normal human cells have turned up key differences from those observed in cancer cells. The distinct binding patterns reflect differences in the chromatin (the way DNA is packed with proteins), which may be important for understanding the function of the tumor suppressor protein in cancer cells.

1 Dec 2011

New approach for identifying 'self' proteins targeted in autoimmune diseases

Researchers from Harvard Medical School and MIT have developed a new approach for identifying the "self" proteins targeted in autoimmune diseases such as multiple sclerosis, diabetes and rheumatoid arthritis.

3 Jun 2011

An alternative solid phase affinity matrix for chromatin immunoprecipitation

Porvair Filtration Group working in collaboration with the Department of Biological Sciences, University of Essex, UK has produced an alternative, high performance Solid Phase Affinity Matrix for Chromatin Immunoprecipitation (ChIP) assays. The research at Essex University evaluating the new BioVyon - Protein A material in ChIP assays is published in the May 2011 issue of Analytical Biochemistry.

From Chromatrap® - Porvair Sciences Ltd 23 May 2011

Chromatrap Pro-A Spin Columns improve ChIP assay performance

Porvair Filtration Group has announced the launch of the first product, a ChIP kit containing 24 assays, based upon its novel Chromatrap™ Pro-A Chromatin ImmunoPrecipitation (ChIP) technology. The exciting new product has been enthusiastically tested at 12 beta sites around the world with excellent results and feedback.

From Chromatrap® - Porvair Sciences Ltd 3 May 2011

NEB, Sequenom sign deal to commercialize research tools for epigenetics

New England Biolabs, Inc. and Sequenom, Inc. jointly announce that they have signed a licensing and co-marketing agreement to commercialize research tools for epigenetics.

From New England Biolabs 6 Apr 2011

OriGene releases 1,500 mouse monoclonal antibodies

OriGene Technologies, Inc. has recently achieved a significant milestone in its quest for developing an assay for every human protein through the release of 1,500 mouse monoclonal antibodies under the TrueMAB brand. Each TrueMAB antibody is specifically developed with full-length human proteins produced in HEK293T cells and validated for critical research and diagnostic needs requiring improved antibody sensitivity and specificity.

21 Jan 2011

Multinational team identifies novel retinal disease gene

A multinational team effort of Regensburg's Institute of Human Genetics, Washington University in St. Louis, other partners and Genomatix elucidated a transcriptional network in photoreceptors and thereby identified a novel retinal disease gene

19 Nov 2010

Elevated levels of MCP-1 found in urine of patients with acute kidney injury

The presence of certain markers in the urine might be a red flag for acute kidney injury (AKI), according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that a simple urine test could help prevent cases of kidney failure.

12 Nov 2010

Gene Biodesign joins Roche NimbleGen Certified Service Provider Program

Roche NimbleGen announced today that Taipei-based genomic services provider Gene Biodesign Enterprises Co. has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program.

13 Oct 2010

Researchers discover new factors that regulate fat formation

By creating a "map" of histone modifications in fat cells, investigators have discovered two new factors that regulate fat formation, a key step on the road to better understanding obesity, diabetes and other metabolic disorders.

1 Oct 2010

Life Technologies debuts Invitrogen MAGic Sample Processor for addressing reproducibility challenges

Life Technologies Corporation today debuted the life science industry's first benchtop sample preparation system designed to increase productivity while eliminating manual and contamination-related challenges traditionally associated with protein and epigenetic protocols. The Invitrogen MAGic™ Sample Processor enables researchers to cut protocol time in half, dramatically reduce experimental errors, and perform technically challenging experiments in protein purification and epigenetics.

26 Apr 2010

Mutations in MeCP2 cause autism spectrum disorder Rett Syndrome

A paper published online today in Molecular Cell proposes that Methyl CpG binding protein 2 (MeCP2) impacts the entire genome in neurons, rather than acting as a regulator of specific genes. Mutations in MeCP2 cause the autism spectrum disorder Rett Syndrome as well as some cases of neuropsychiatric problems including autism, schizophrenia and learning disabilities.

26 Feb 2010

Helicos BioSciences to demonstrate single molecule sequencing using Helicos Genetic Analysis System

Helicos BioSciences and it’s collaborators will deliver presentations featured at the Advances in Genome Biology and Technology (AGBT) meeting in Marco Island, Florida, from February 24-27, 2010.

26 Feb 2010

Diagenode launches SX-8G IP-Star system for epigenetics

Diagenode, an innovative leader providing products and technologies for epigenetics, genomics and diagnostics, and the only provider of complete epigenetics solutions, announced today the launch of its innovative platform for automated epigenetics assays, the SX-8G IP-Star™ system ("IP-Star™).

16 Feb 2010

imaGenes achieves Roche NimbleGen CSP-status for ChIP-chip application

Roche NimbleGen has announced that imaGenes GmbH, a Berlin-based genomics & proteomics specialist, has achieved status as a Certified Service Provider (CSP) of NimbleGen microarrays for Chromatin Immunoprecipitation (ChIP-chip). imaGenes GmbH has passed a rigorous ChIP-chip certification to officially become part of the Roche NimbleGen Certified Service Provider Program.

16 Dec 2009

Precision Antibody to develop antibodies for NCI's Clinical Proteomic Technologies for Cancer

Precision Antibody(TM) has been selected as the antibody developer for a component of the National Cancer Institute (NCI)'s Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.

28 Oct 2009

BH3 profiling can help in determining cancer's chemosensitivity

Two different anti-apoptotic proteins support cancer cell survival via an identical mechanism, yet differ in their sensitivity to chemotherapeutic drugs, report Brunelle et al. The study will be published online October 26, 2009 and in the November 2, 2009 print issue of the Journal of Cell Biology (JCB).

27 Oct 2009

Research reveals that large non-coding RNA in mammals play an important role in telomere maintenance

A team of researchers from The Wistar Institute have shown that a large non-coding RNA in mammals and yeast plays a central role in helping maintain telomeres, the tips of chromosomes that contain important genetic information and help regulate cell division. Since this RNA also facilitates the formation of DNA at telomeres-a process that can protect aging cells and destabilize tumor cells-manipulating its expression may be useful in treating cancer and other diseases.

1 Sep 2009